Hyperoncotic Albumin Reduces Net Fluid Loss Associated With Hemodialysis

Mitchell S. Buckley, Brian L. Erstad, Jake M. Lansburg, Sumit K. Agarwal

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: The purpose of this study was to compare the volume of fluid removal associated with and without 25% albumin administration in conjunction with hemodialysis. Methods: This retrospective, cohort study was conducted at a large academic medical center over a 6-month period to compare the net fluid amount removed (mL) during hemodialysis between patients administered 25% albumin and those without albumin. Results: A total of 238 patients consisting of 973 unique hemodialysis sessions were evaluated. The mean overall net fluid removed by hemodialysis in the 25% albumin and no albumin groups were 1242 mL and 1899 mL, P <.001, respectively. No albumin group had significantly higher mean fluid losses compared with 25% albumin for a total dose of either 25 g (P =.001) or 50 g (P =.001). There were no significant differences in mean fluid loss between the no albumin group and patients receiving 75 g or 100 g of albumin. Post hoc analysis failed to demonstrate a dose-dependent response in those patients receiving 25% albumin and no albumin. Conclusion: Hyperoncotic albumin administered during hemodialysis sessions reduced net fluid loss associated with hemodialysis. The findings of this study do not support the routine use of 25% albumin to improve fluid removal during dialysis.

Original languageEnglish (US)
Pages (from-to)130-134
Number of pages5
JournalHospital Pharmacy
Issue number2
StatePublished - Apr 1 2020


  • colloid
  • fluid
  • hemodialysis
  • human serum albumin

ASJC Scopus subject areas

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Hyperoncotic Albumin Reduces Net Fluid Loss Associated With Hemodialysis'. Together they form a unique fingerprint.

Cite this